Medicure Inc experienced a remarkable uptick in its stock price, gaining over 24% in a single trading session.
In yesterday's session, Medicure Inc (MPH.V) saw its stock price surge by 24.16%, closing at CA$3.70. This increase reflects growing investor interest and confidence in the company's future prospects.
Advertisement
Medicure Inc
MPH.V
MPH.V
Medicure Inc
WealthAwesomeMarket cap
$31.10M
52W high
$4.95
52W low
$0.85
1W change
+26.28%
Beta
1.15
Analyst Price Targets
Based on analyst covering MPH · as of Sep 17, 2026
Wall Street analysts forecast MPH stock price to fall 24.3% over the next 12 months.
Consensus
BearishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$2.80
-24.3% Upside
Current Price
C$3.70
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on MPH's historical volatility
30-Day Vol
125.8%
Annualized
90-Day Vol
135.9%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$4.42
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$3.93 | C$2.54 – C$6.06 |
| 60 trading days | C$4.17 | C$2.26 – C$7.70 |
| 90 trading days | C$4.42 | C$2.09 – C$9.38 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: The surge in Medicure's stock price suggests a positive market sentiment, likely driven by recent developments in its clinical trials and business expansions.
Medicure Inc's stock price jumped 24.16% yesterday.
Advertisement
The company's market cap now stands at CA$38.6 million, reflecting its growing valuation amidst recent developments.
Bull case
The completion of the MEND-PNPO Phase 3 clinical trial enrollment may indicate progress in Medicure's research and development efforts, which could lead to future revenue growth. With 10 patients enrolled, the company is making strides in addressing PNPO deficiency, potentially opening new revenue streams. This progress may have contributed to the stock's impressive performance as investors seek growth opportunities.
Bear case
Despite the recent surge, Medicure reported a net loss of CA$7.1 million for 2025, highlighting ongoing challenges that investors should consider. While the stock has surged, it’s crucial to evaluate the company's financial health. Investors need to weigh the potential for growth against these financial challenges as Medicure continues to expand its business, including recent pharmacy acquisitions. The market will be watching closely for signs of improvement.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
